Kiniksa Pharmaceuticals International, plc
78.52USD
+1.4300 (+1.85%)
Computing valuation metrics…
Valuation
P/E (TTM)
83.86x
P/E (Forward)
48.54x
EV/EBITDA
58.37x
EV/Revenue
7.29x
P/S (TTM)
8.12x
P/B
10.11x
FCF Yield
2.68%
Dividend Yield
0.00%
Gross Margin
89.31%
Operating Margin
12.36%
Net Margin
9.69%
Peer Comparison — Drug Manufacturers - Specialty & Generic
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| KNSAKiniksa Pharmaceuticals International, plc | $6.13B | 83.86x | 58.37x | 2.68% | 55.51% | 0.00% |
| TEVATeva Pharmaceutical Industries Limited | $42.84B | 61.27x | 13.14x | 5.18% | -0.80% | — |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $30.29B |
| 11.96x |
| 9.31x |
| 6.66% |
| -0.20% |
| 2.88% |
| VTRSViatris Inc. | $18.95B | — | 7.27x | 14.13% | 4.90% | 2.89% |
| HIMSHims & Hers Health, Inc. | $6.51B | — | — | 13.05% | 38.20% | — |
| LQDALiquidia Corporation | $6.19B | 49.37x | 35.09x | 1.20% | 1842.70% | — |
| AMLXAmylyx Pharmaceuticals, Inc. | $3.61B | — | — | -2.14% | — | — |
| BHCBausch Health Companies Inc. | $2.30B | — | 5.71x | 62.23% | 12.70% | — |
| ADCTADC Therapeutics SA | $165.97M | — | — | -41.04% | 2.20% | — |